Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on August 5, 2021. The filing reports financial results for the three and six months ended June 30, 2021, along with recent corporate updates. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol SLRX.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing announces the release of financial results for the periods ended June 30, 2021. No specific material changes compared to prior periods are quantified in the text of this 8-K.
Guidance, Outlook, and Risks
The filing includes "other recent corporate updates" alongside the financial results, but the specific content of management commentary, guidance, outlook, or risks is not detailed in the provided text. The information is furnished and explicitly stated as not being "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in Exhibit 99.1 (Press Release dated August 5, 2021).
- Confirm the details of the "recent corporate updates" mentioned in Item 2.02.
- Note that the registrant name in the filing is Salarius Pharmaceuticals, Inc., which differs from the metadata field "Decoy Therapeutics Inc."
- Review the full press release for any forward-looking statements or risk factors not summarized in this 8-K.